Mechanisms for cachexia in heart failure (Q38127358)

29 August 2017

title

Mechanisms for cachexia in heart failure (English)

1 reference

29 August 2017

0 references

Vincent Pureza

1 reference

29 August 2017

Viorel G Florea

series ordinal

1 reference

29 August 2017

publication date

1 December 2013

1 reference

Current heart failure reports

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

307-314

1 reference

Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Diseases of the heart in the works of Hippocrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Changing epidemiological features of cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Wasting as independent risk factor for mortality in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

ABC of heart failure. Non-drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Branched-chain amino acid supplementation during bed rest: effect on recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Altered intestinal function in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Systemic inflammation in heart failure--the whys and wherefores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Basic mechanisms in heart failure: the cytokine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Cachexia: a therapeutic approach beyond cytokine antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Traditional and novel approaches to management of heart failure: successes and failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Vascular inflammation and the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The importance of the gastrointestinal system in the pathogenesis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Beta-blockers and weight change in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

THE PATHOGENESIS OF CARDIAC CACHEXIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Cardiac cachexia: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Growth hormone resistance in chronic heart failure and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

A placebo-controlled study of growth hormone in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Ghrelin induces adiposity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The biology of leptin: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The relationship between obesity and mortality in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The obesity paradox, cardiorespiratory fitness, and coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Metabolic and nutritional disorders in cardiac cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The role of exercise training in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Cytokines, apoptosis and cachexia: the potential for TNF antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Oxpentifylline in endotoxaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Immunological mechanisms of pentoxifylline in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

ESPEN Guidelines on Parenteral Nutrition: On Cardiology and Pneumology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0153-9

The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy

21 January 2018

1 reference

12 December 2020

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

1 reference

12 December 2020

Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure

1 reference

12 December 2020

Adrenergic effects on the biology of the adult mammalian cardiocyte

1 reference

12 December 2020

Malnutrition in dilated cardiomyopathy. Correlation with echocardiographic indices of left ventricular function

1 reference

12 December 2020

Systemic inflammation in patients with heart failure

1 reference

12 December 2020

Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure

1 reference

12 December 2020

How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH

1 reference

12 December 2020

Heart failure-induced cachexia

1 reference

12 December 2020

Elevated soluble CD14 receptors and altered cytokines in chronic heart failure

1 reference

12 December 2020

The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells

1 reference

12 December 2020

Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure

1 reference

12 December 2020

Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo

1 reference

12 December 2020

Energy expenditure and symptom severity in men with heart failure

1 reference

12 December 2020

Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

1 reference

12 December 2020

Pentoxifylline suppression of tumor necrosis factor gene transcription

1 reference

12 December 2020

Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia

1 reference

12 December 2020

Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

1 reference

12 December 2020

Growth hormone in the treatment of dilated cardiomyopathy

1 reference

12 December 2020

Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation

1 reference

12 December 2020

Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure

1 reference

12 December 2020

Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity

1 reference

12 December 2020

10.1007/S11897-013-0153-9

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1029118286

0 references

1 reference